Story of Nanologica
Read more:
Story of nanologica
Nanologica is a Swedish life science tools company that provides advanced consumables to pharmaceutical manufacturers.
The company was founded in 2004 and stems from research within material sciences on the synthesis, analysis, and characterization of new porous materials. With a foundation in materials science and nanotechnology, the company has developed an expertise in chromatography. Today, Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles.
Nanologica’s products are used to purify pharmaceuticals during production using a technique called preparative chromatography. Our silica-based purification media for preparative chromatography, NLAB Saga®, has been especially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues.
Through a proprietary production method, we create world-class silica-based products that can purify more effectively and that last longer. This can reduce production costs and increase productivity for pharmaceutical manufacturers, making staple medicines available to more patients. Our mission is to increase the availability of cost-effective drugs, enabling more patients around the world access to vital treatments for diabetes and obesity.
Nanologica has full control of the entire manufacturing process, from raw material to finished product. NLAB Saga® has been tested and used by pharmaceutical companies worldwide manufacturing APIs at industrial scale where quality, performance and durability are uncompromisable.
At the headquarter in Södertälje, Sweden, we develop new products and have customer support in the form of application support and method development, as well as production of silica on a smaller scale. For large-scale production, the company works together with partners. Large-scale production of silica takes place at a contract manufacturer in the UK and Ireland, in factories with multi-ton scale capacity.
Nanologica has a proven ability to identify and develop strong product concepts. To create the best possible preconditions for development and growth, Nanologica has at times chosen to spin out business concepts into separate entities. The first was Exeger (solar cells for indoor use) in 2011, and the second was Sigrid Therapeutics (treatment for obesity) in 2014.
In 2015 the company’s share (NICA) was listed for trade on Spotlight Stock Market and since 2022 the share is listed on Nasdaq Stockholm Main Market.